Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
Gemlapodect by Noema Pharma for Stammering (Stuttering): Likelihood of Approval
Gemlapodect is under clinical development by Noema Pharma and currently in Phase II for Stammering (Stuttering). According to GlobalData, Phase...
Data Insights
Gemlapodect by Noema Pharma for Tourette Syndrome: Likelihood of Approval
Gemlapodect is under clinical development by Noema Pharma and currently in Phase II for Tourette Syndrome. According to GlobalData, Phase...